Incidence and Clinical Practice of Exudative Age-related Macular Degeneration

• DOI: 10.1016/j.xops.2022.100125
• Publication Date: 2022-03-01T08:04:08Z
• Authors: Ai Kido; Masahiro Miyake; Hiroshi Tamura; Shusuke Hiragi; Takeshi Kimura; Satomi Yoshida; Masato Takeuchi; Shosuke Ohtera; Ayako Takahashi; Sotaro Ooto; Koji Kawakami; Tomohiro Kuroda; Akitaka Tsujikawa
• Keywords: Christian ministry; National Health Insurance; Rate ratio

To elucidate the incidence and treatment pattern of active exudative age-related macular degeneration (AMD).A population-based cohort study conducted using National Database Health Insurance Claims Specific Checkups Japan (NDB), a national claims database managed by Japanese Ministry Health, Labour, Welfare (MHLW).The entire population aged 40 years or older (76 million people).With permission MHLW, we accessed complete NDB dataset identified patients with newly diagnosed AMD between 2011 2018. The was categorized age sex per year 2018; moreover, details regarding first-line therapy number anti-vascular endothelial growth factor (VEGF) injections elapsed since initial were obtained changes in investigated.Incidence rate AMD.During specified 8-year period, 246 064 incident cases identified; 61.4% these men. overall 40.66 100 000 person-years (95% confidence interval [CI], 40.49-40.82) general older, 53.22 CI, 52.95-53.49) men, 29.78 29.60-29.98) women. Mean onset lower men than women (72.51 ± 10.50 vs. 73.90 10.46 years). Among AMD, 92.9% received anti-VEGF for treatments, whereas 1.8% underwent combination photodynamic therapy. first (0-12 months), second (13-24 third (25-36 months) after injection 3.66 2.30, 1.39 2.20, 1.23 2.19, respectively. Patients who fewer subsequent vice versa.This is relatively large on detailed epidemiology actual patterns clinical practice. Our results can be fundamental information source to ensure healthy eyes promote well-being all at ages.